PharmaFocus Today – Page 10 – media

Renmin Pharmaceutical’s revenue in 2024 is 25.435 billion yuan, and the controlling shareholder’s reorganization is about to be implemented

On the evening of April 28, Renmin Pharmaceutical disclosed its 2024 annual report. The company achieved operating income of 25.435 billion yuan for the whole year, a year-on-year increase of 3.71%; net profit attributable to the parent company was 1.33 billion yuan. The first quarter report on the same day showed that the company’s current operations continued to be stable, with operating income of 6.137 billion yuan; net profit attributable to the parent company was 540 million yuan, a year-on-year increase of 11.09%. In addition, the bankruptcy reorganization of the company’s controlling shareholder Contemporary Group is progressing smoothly. The announcement shows that the reorganization plan has been approved by the court. After the reorganization is implemented, China Merchants Group’s China Merchants Innovation and Technology may become a strategic investor in the listed company. The financial report shows that in 2024, Renmin Pharmaceutical’s net profit attributable to the parent company decreased ...
- Source: drugdu
- 65
- April 30, 2025
Tasly’s pharmaceutical industry revenue grew steadily in the first quarter

On the evening of April 28, Tasly (600535) released its first quarter report for 2025. During the reporting period, the company achieved pharmaceutical industry revenue of 1.842 billion yuan, a year-on-year increase of 1.83%. The company achieved a net profit of 314 million yuan attributable to its parent company in the first quarter, a year-on-year increase of 6.47%. In the first quarter, the company’s traditional Chinese medicine sector achieved revenue of 1.469 billion yuan, a year-on-year increase of 1.90%. On March 28, the company announced that the transfer and registration of shares between the original controlling shareholder Tasly Group and its concerted actors and China Resources Sanjiu and Guoxin Investment has been completed. China Resources Sanjiu became the company’s controlling shareholder, and the actual controller was changed to China Resources Co., Ltd. With the completion of the transaction, Tasly also announced major adjustments to the board of directors and the ...
- Source: drugdu
- 68
- April 30, 2025
Hualan Vaccine’s net profit attributable to the parent company in the first quarter was 32.78 million yuan, a year-on-year decrease of 15.1%

On April 27, Hualan Vaccine (301207) announced the first quarter report of 2025. The company’s operating income was 24.28 million yuan, a year-on-year decrease of 29.0%; the net profit attributable to the parent company was 32.78 million yuan, a year-on-year decrease of 15.1%; the net profit attributable to the parent company after deducting non-recurring items was 15.42 million yuan, a year-on-year increase of 8.9%; the net cash flow from operations was -2.59 million yuan, a year-on-year decrease of 102.7%; EPS (fully diluted) was 0.0545 yuan. As of the end of the first quarter, the company’s total assets were 7.443 billion yuan, a decrease of 1.1% from the end of the previous year; the net assets attributable to the parent company were 6.048 billion yuan, an increase of 0.6% from the end of the previous year. The company mainly focuses on the research and development, production and sales of biological vaccines, ...
- Source: drugdu
- 62
- April 30, 2025
Multiple positive factors combined with the pharmaceutical themed fund ‘hardship over sweetness’

At the end of the first quarter of this year, several active equity funds with heavy holdings in the humanoid robot sector were still far ahead in performance, while recently, funds with heavy holdings in the innovative medicine sector have stood out. As of April 27th, the Huitianfu Hong Kong Advantage Selection Hybrid (QDII) A managed by fund manager Zhang Wei has become the best performing public offering product of the year with a return rate of 64.44%. Industry insiders have stated that compared to the past, the market for innovative drugs in this round is more rational. Firstly, the industry trends and policy guidance have become clearer, leading to an increase in market confidence; Secondly, many key companies’ core products have already been listed or validated with critical clinical data, resulting in a significant increase in investment success rates; Thirdly, some leading companies are about to cross the ...
- Source: drugdu
- 80
- April 29, 2025
The new version of the National Health Supervision and Inspection Plan has been released, which for the first time explicitly targets online “medical trusts”

NO.1 clarifies for the first time to crack down on online “medical trusts” The National Center for Disease Control and Prevention and three other departments recently jointly released the “2025 National Random Supervision and Sampling Plan” for the medical and health field. Compared with the 2024 plan, the 2025 plan will make adjustments in the scope of supervision, add new areas of supervision such as Internet diagnosis and treatment, mental health, and for the first time explicitly crack down on new illegal behaviors such as online “medical care”, further strengthen the governance of public health and medical order. Comment: The clear crackdown on online “medical trusts” in regulation is a powerful upgrade to medical supervision. The concealment of online “medical care” is strong, seriously disrupting medical order and damaging patient rights. It is expected to purify the medical network space with the supervision of new fields such as Internet ...
- Source: drugdu
- 75
- April 29, 2025
Hualan Vaccine’s net profit attributable to the parent company in the first quarter was 32.78 million yuan, a year-on-year decrease of 15.1%

On April 27, Hualan Vaccine (301207) announced the first quarter report of 2025. The company’s operating income was 24.28 million yuan, a year-on-year decrease of 29.0%; the net profit attributable to the parent company was 32.78 million yuan, a year-on-year decrease of 15.1%; the net profit attributable to the parent company after deducting non-recurring items was 15.42 million yuan, a year-on-year increase of 8.9%; the net cash flow from operations was -2.59 million yuan, a year-on-year decrease of 102.7%; EPS (fully diluted) was 0.0545 yuan. As of the end of the first quarter, the company’s total assets were 7.443 billion yuan, a decrease of 1.1% from the end of the previous year; the net assets attributable to the parent company were 6.048 billion yuan, an increase of 0.6% from the end of the previous year. The company mainly focuses on the research and development, production and sales of biological vaccines, ...
- Source: drugdu
- 92
- April 29, 2025
The incidence of vaccine-preventable diseases is rising

According to the official website of the World Health Organization (WHO) on April 24, during the “World Immunization Week” held from the 24th to the 30th, WHO, UNICEF and the Global Vaccine Immunity Alliance jointly issued a warning that due to the spread of misinformation and the reduction of international aid, diseases that could have been prevented by vaccines, such as measles, meningitis and yellow fever, are on the rise worldwide. The three major international organizations urgently called on countries to continue to invest political attention and funds to consolidate the results of immunization programs and safeguard the significant progress made in reducing child mortality in the world over the past half century. The latest monitoring data show that measles cases have increased year by year since 2021. In 2023, there were 10.3 million cases, an increase of 20% from 2022. In the past 12 months, 138 countries have reported ...
- Source: drugdu
- 84
- April 29, 2025
Clinical trial of carrelizumab injection approved

Hengrui Medicine(600276) announced on the evening of April 27 that its subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for injection of carrelizumab approved by the National Medical Products Administration, and will conduct clinical trials in the near future. Carrelizumab injection is a humanized anti-PD-1 monoclonal antibody that can bind to the human PD-1 receptor and block the PD-1/PD-L1 pathway, restoring the body’s anti-tumor immunity, thereby forming a cancer immunotherapy base. https://finance.eastmoney.com/a/202504273390129236.html
- Source: drugdu
- 77
- April 29, 2025
The UN warns that the incidence rate of vaccine preventable diseases is rising

According to the official website of the World Health Organization (WHO) on April 24th, during the “World Immunization Week” held from the 24th to the 30th, WHO、 The United Nations Children’s Fund and the Global Alliance for Vaccines and Immunization have jointly issued a warning that diseases that could have been prevented by vaccines, such as measles, meningitis, and yellow fever, are on the rise globally due to the spread of misinformation and reduced international aid. These three major international organizations urgently call on countries to continue investing political attention and funding to consolidate the achievements of immunization programs and safeguard the significant progress made globally in reducing child mortality rates over the past half century. The latest monitoring data shows that since 2021, the number of measles cases has been increasing year by year. By 2023, the number of cases will reach 10.3 million, an increase of 20% ...
- Source: drugdu
- 76
- April 28, 2025
Enoxaparin Sodium Injection Obtains South African Drug Registration Approval

Hepalink announced on the evening of April 24 that its wholly-owned subsidiary Tiandao Pharmaceutical recently received an approval notice for Enoxaparin Sodium Injection issued by the South African Health Products Administration. The drug can be used before and after surgery to prevent or prevent blood clots in the blood. This approval means that Hepalink’s Enoxaparin Sodium preparations can be sold in the South African market. Hepalink disclosed its first quarter report for 2025 on the same day, with a net profit attributable to shareholders of 157 million yuan in the first quarter, a year-on-year increase of 1%. https://finance.eastmoney.com/a/202504243387456384.html
- Source: drugdu
- 76
- April 28, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.